Birdwatch Archive

Birdwatch Note

2024-12-18 12:43:11 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

書籍名の「販売を命じられた」によれば開発担当ではありません。 前書きによれば非公開情報や企業の内部情報はなく、暴露本ではない門外漢の感想文です https://www.amazon.co.jp/dp/B0DHCYPZJ2?asin=B0DHCYPZJ2&revisionId=e84ae297&format=3&depth=1 https://x.com/WideRangeThink/status/1847501454090858990 以下の指摘をする記事もあります https://www.nikkan-gendai.com/articles/view/life/365156 コスタイベ(レプリコンワクチン)の安全性と有効性は治験で良好と評価されています https://doi.org/10.1038/s41467-024-47905-1 https://www.mhlw.go.jp/content/10906000/001316061.pdf https://www.pmda.go.jp/drugs/2024/P20240917001/780009000_30500AMX00282_A100_1.pdf https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#20 従来型も世界中の継続かつ徹底した科学的検証でワクチンによる被害は皆無か、極めて稀である可能性が高いと言えます https://www.mhlw.go.jp/content/10900000/000796742.pdf https://www.niid.go.jp/niid/ja/others.html https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines-safety https://doi.org/10.1016/S1473-3099(22)00320-6 https://warp.ndl.go.jp/info:ndljp/pid/13123205/www.cov19-vaccine.mhlw.go.jp/qa/0081.html https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#31 https://www.mhlw.go.jp/stf/shingi/shingi-kousei_284075.html IF値の高い医学誌・科学誌の査読済論文、WHOや先進国民主主義の政府機関の公式発表等の原典を参照しましょう https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#36 https://togetter.com/li/2416068 https://togetter.com/li/2131189 https://togetter.com/li/2174198

Written by EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1869187286006743435

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1869362776235467204
  • noteId - 1869362776235467204
  • participantId -
  • noteAuthorParticipantId - EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00 Participant Details
  • createdAtMillis - 1734525791593
  • tweetId - 1869187286006743435
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 1
  • misleadingManipulatedMedia - 0
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 0
  • misleadingUnverifiedClaimAsFact - 1
  • misleadingSatire - 1
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • 書籍名の「販売を命じられた」によれば開発担当ではありません。 前書きによれば非公開情報や企業の内部情報はなく、暴露本ではない門外漢の感想文です https://www.amazon.co.jp/dp/B0DHCYPZJ2?asin=B0DHCYPZJ2&revisionId=e84ae297&format=3&depth=1 https://x.com/WideRangeThink/status/1847501454090858990 以下の指摘をする記事もあります https://www.nikkan-gendai.com/articles/view/life/365156 コスタイベ(レプリコンワクチン)の安全性と有効性は治験で良好と評価されています https://doi.org/10.1038/s41467-024-47905-1 https://www.mhlw.go.jp/content/10906000/001316061.pdf https://www.pmda.go.jp/drugs/2024/P20240917001/780009000_30500AMX00282_A100_1.pdf https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#20 従来型も世界中の継続かつ徹底した科学的検証でワクチンによる被害は皆無か、極めて稀である可能性が高いと言えます https://www.mhlw.go.jp/content/10900000/000796742.pdf https://www.niid.go.jp/niid/ja/others.html https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines-safety https://doi.org/10.1016/S1473-3099(22)00320-6 https://warp.ndl.go.jp/info:ndljp/pid/13123205/www.cov19-vaccine.mhlw.go.jp/qa/0081.html https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#31 https://www.mhlw.go.jp/stf/shingi/shingi-kousei_284075.html IF値の高い医学誌・科学誌の査読済論文、WHOや先進国民主主義の政府機関の公式発表等の原典を参照しましょう https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#36 https://togetter.com/li/2416068 https://togetter.com/li/2131189 https://togetter.com/li/2174198

Note Ratings

rated at rated by
2024-12-18 18:43:25 -0600 Rating Details
2024-12-18 18:09:51 -0600 Rating Details
2024-12-18 15:09:25 -0600 Rating Details
2024-12-18 12:46:27 -0600 Rating Details
2024-12-18 09:10:35 -0600 Rating Details
2024-12-18 08:44:57 -0600 Rating Details
2024-12-18 08:18:30 -0600 Rating Details
2024-12-18 08:17:51 -0600 Rating Details
2024-12-18 08:15:21 -0600 Rating Details
2024-12-18 07:45:02 -0600 Rating Details
2024-12-18 06:58:47 -0600 Rating Details
2024-12-20 17:22:50 -0600 Rating Details
2024-12-20 00:00:09 -0600 Rating Details
2024-12-19 22:20:48 -0600 Rating Details
2024-12-19 18:06:06 -0600 Rating Details
2024-12-19 17:33:52 -0600 Rating Details
2024-12-19 14:01:27 -0600 Rating Details
2024-12-19 10:34:39 -0600 Rating Details
2024-12-19 09:09:39 -0600 Rating Details
2024-12-19 09:02:23 -0600 Rating Details
2024-12-19 08:18:38 -0600 Rating Details
2024-12-19 07:01:11 -0600 Rating Details
2024-12-19 06:34:22 -0600 Rating Details
2024-12-19 06:20:52 -0600 Rating Details
2024-12-19 06:08:02 -0600 Rating Details
2024-12-19 05:59:47 -0600 Rating Details
2024-12-19 05:49:16 -0600 Rating Details
2024-12-19 04:59:34 -0600 Rating Details
2024-12-19 04:25:21 -0600 Rating Details
2024-12-19 04:21:05 -0600 Rating Details
2024-12-19 03:39:21 -0600 Rating Details
2024-12-19 03:24:04 -0600 Rating Details
2024-12-19 03:21:11 -0600 Rating Details
2024-12-19 02:48:29 -0600 Rating Details
2024-12-19 02:41:16 -0600 Rating Details
2024-12-19 02:15:04 -0600 Rating Details
2024-12-19 02:07:00 -0600 Rating Details
2024-12-19 01:23:50 -0600 Rating Details
2024-12-18 21:50:35 -0600 Rating Details
2024-12-18 21:28:05 -0600 Rating Details
2024-12-21 08:18:33 -0600 Rating Details
2024-12-21 06:31:46 -0600 Rating Details
2024-12-21 05:06:39 -0600 Rating Details
2024-12-21 04:56:59 -0600 Rating Details
2024-12-21 03:14:00 -0600 Rating Details
2024-12-20 23:07:46 -0600 Rating Details
2024-12-20 19:55:15 -0600 Rating Details
2024-12-19 20:52:10 -0600 Rating Details
2024-12-19 15:39:44 -0600 Rating Details
2024-12-19 10:32:11 -0600 Rating Details
2024-12-19 08:19:09 -0600 Rating Details
2024-12-19 07:49:56 -0600 Rating Details
2024-12-19 07:28:15 -0600 Rating Details
2024-12-19 05:20:09 -0600 Rating Details
2024-12-19 03:47:17 -0600 Rating Details
2024-12-19 03:17:31 -0600 Rating Details
2024-12-19 02:07:20 -0600 Rating Details
2024-12-19 01:35:23 -0600 Rating Details
2024-12-19 01:30:46 -0600 Rating Details
2024-12-19 01:01:45 -0600 Rating Details
2024-12-18 23:53:35 -0600 Rating Details
2024-12-18 21:24:18 -0600 Rating Details
2024-12-18 17:00:17 -0600 Rating Details
2024-12-18 10:04:25 -0600 Rating Details
2024-12-18 09:09:17 -0600 Rating Details
2024-12-18 07:58:27 -0600 Rating Details
2024-12-18 07:35:41 -0600 Rating Details
2024-12-18 07:04:34 -0600 Rating Details
2024-12-24 21:55:05 -0600 Rating Details
2024-12-24 19:09:37 -0600 Rating Details
2024-12-21 11:04:43 -0600 Rating Details
2024-12-20 09:43:58 -0600 Rating Details
2024-12-20 05:23:00 -0600 Rating Details
2024-12-19 22:12:11 -0600 Rating Details
2024-12-19 17:50:33 -0600 Rating Details
2024-12-19 14:46:44 -0600 Rating Details
2024-12-19 12:15:50 -0600 Rating Details
2024-12-19 09:17:07 -0600 Rating Details
2024-12-19 07:59:13 -0600 Rating Details
2024-12-19 03:55:11 -0600 Rating Details
2024-12-19 03:23:29 -0600 Rating Details
2024-12-19 03:14:52 -0600 Rating Details
2024-12-19 02:40:57 -0600 Rating Details
2024-12-19 00:38:11 -0600 Rating Details
2024-12-18 22:41:14 -0600 Rating Details
2024-12-18 08:55:52 -0600 Rating Details
2024-12-18 08:41:48 -0600 Rating Details
2024-12-18 07:54:49 -0600 Rating Details
2024-12-18 07:51:34 -0600 Rating Details